SEC Form 4 · accession 0001171000-15-000045
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Damian T. Lismore
Officer — CHIEF FINANCIAL OFFICER
Period of report
Jul 1, 2015
Accepted (ET)
Jul 2, 2015 · 1:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 1, 2015 | M | 4,000 | $0.125 | A | 10,000 | D | |
| Ordinary SharesF1 | holding | — | — | — | 13,724 | I | Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C> | |
| Ordinary Shares | holding | — | — | — | 7,080 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase StockF2 | $0.125 | Jul 1, 2015 | M | 4,000 | D | Jul 1, 2015 | Jul 1, 2019 | Ordinary Shares | 4,000 | 14,000 | D |
Explanation of responses
- F1The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- F24,000 options vested and became exercisable on 7/1/15; 4.000 options shall vest and become exercisable on each of 7/1/16 and 7/1/17. The remaining 6,000 options will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by the Issuer's board of directors; such completion must occur on or before 7/1/19